Detection of XXXX by serologic screening and clinical examination.

@entity1 @entity5 @entity189 @entity2025
In a prospective study, 42 048 adults residing in Zhongshan City, Guangdong, China, were followed for 16 years, and 171 of them developed @entity189 ( @entity189 ). Although @entity2025 ( @entity2025 ) antibody levels of the cohort fluctuated, the antibody levels of 93% of the @entity1 with @entity189 were raised and maintained at high levels for up to 10 years prior to diagnosis. This suggests that the serologic window affords an opportunity to monitor @entity5 progression during the preclinical stage of @entity189 development, facilitating early @entity189 detection. We reviewed the clinical records of the 171 @entity1 with @entity189 in the prospective study to assess the efficacy of early @entity189 detection by serologic screening and clinical examination. Of the 171 @entity1 , 51 had Stage I @entity5 (44 were among the 73 @entity1 detected by clinical examination and 7 were among the 98 @entity1 presented to outpatient department). Initial serologic screening predicted 58 (95.1%) of the 61 @entity1 detected within 2 years. The risk of the screened population (58/3093) raised 13 times relative to cohort (61/42 048) during this period. Clinical examination detected all the 58 predicted cases, and 35 (60.3%) of which were diagnosed with Stage I @entity5 . The serologic prediction rate fell to 33.6% (37/110) 2 to 16 years after screening. The proportion of cases detected by clinical examination fell to 40.5% (15/37). The proportion of Stage I @entity5 among the cases detected by clinical examination during both periods remained at about 60%. We concluded that early detection of @entity189 can be accomplished by repeated serologic screening to maintain high prediction rates and by promptly examining screened subjects to detect @entity5 before the symptoms develop.
